1. A randomized double‐blind, placebo‐controlled study of therapeutic effects of silymarin in β‐thalassemia major patients receiving desferrioxamine. (20th January 2013) Authors: Moayedi, Behjat; Gharagozloo, Marjan; Esmaeil, Nafiseh; Maracy, Mohammad R.; Hoorfar, Hamid; Jalaeikar, Mohsen Journal: European journal of haematology Issue: Volume 90:Number 3(2013:Mar.) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, In Patients with β-Thalassemia Major. (August 2013) Authors: Esmaeil, Nafiseh; Moayedi, Behjat; Gharagozloo, Marjan; Maracy, Mohamad Reza Journal: Hemoglobin Issue: Volume 37:Number 4(2013) Page Start: 404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Serum levels of TGFβ, IL-10, IL-17, and IL-23 cytokines in β-thalassemia major patients: the impact of silymarin therapy. (August 2014) Authors: Balouchi, Sima; Gharagozloo, Marjan; Esmaeil, Nafiseh; Mirmoghtadaei, Milad; Moayedi, Behjat Journal: Immunopharmacology and immunotoxicology Issue: Volume 36:Number 4(2014:Aug.) Page Start: 271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia. Issue 1 (24th January 2022) Authors: Reisi, Nahid; Esmaeil, Nafiseh; Gharagozloo, Marjan; Moayedi, Behjat Journal: Clinical case reports Issue: Volume 10:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗